吉祥坊登录

Beijing, China—Recently, Shanghai MicroPort Endovascular MedTech(Group) Co., Ltd. (“Endovastec™”), successfully held the first International Thoracic Endovascular Aortic Repair (TEVAR) MasterClass. This online class invited ten experts from China and Europe, including Professor Chang Shu, Director of the Vascular Surgery Center of Fuwai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases and Prof. Franco Grego, the incumbent President of the European Society of Cardiovascular Surgery (ESCVS) and Director of Vascular Surgery Department at Padua University Hospital. During the Masterclass, the experts conducted in-depth exchanges and discussions on the cutting-edge developments and academic insights on TEVAR. More than a hundred participants watched the live streaming and participated in discussions online.

Prof. Shu and his team were invited to present two live streaming TEVAR surgery using the Castor™ Branched Aortic Stent-Graft System ("Castor™ Stent") and the Hercules™ Thoracic Stent-Graft System ("Hercules™ Stent”).

The first procedure was performed on a 69-year-old male patient. Preoperative CTA showed a traumatic pseudoaneurysm involving the aortic arch with a maximum diameter of 39 mm. Using the Castor™ Stent, Prof. Shu and his team completed the endovascular repair for integrated supra- aortic arch with an integrated branched stent graft within only 30 minutes. The surgery was a success based on the postoperative angiography, which showed the Castor™ Stent was tightly attached to the vessel wall, ensuring smooth blood flow in left subclavian artery. Experts from Europe and Prof. Shu discussed the intraoperative positioning issue of the Castor™ stent, as well as the unibody design, indications and other related issues. 

The second live procedure was performed on a 72-year-old female patient who was hospitalized for persistent severe chest pain. Preoperative CTA showed an intramural hematoma of the aorta involving the aortic arch and the left subclavian artery, with an ulcer at the descending aorta. Given the patient’s severe stenosis of the access artery, it was a challenge to use endovascular repair to introduce the delivery system. Hercules™ stent selected by the team features a low profile design that reduces the outer diameter of the delivery sheath from 22-24 F of conventional stents to 18 F (6mm), which allows the stent to cross more stenotic vessels. The stent graft can easily cross the aortic arch with the protection of the soft inner sheath, which reduces crossing resistance of the stent system. The product features a tip-capture mechanism, which, with the support of the nitinol wire, results in a significant improvement in both accuracy and stability of stent positioning and deployment. The operation took only 20 minutes. And postoperative angiogram showed a full success by good proximal apposition without endoleak and complete isolation of the ulcer. After the operation, Prof. Shu shared with the European experts on such topics as Hercules™’s low profile design, product features and clinical experience since its launch in China, while other experts shared their insights on the case itself and the cutting-edge progress of TEVAR.

To date, Castor™ stents have been clinicall applied in Poland, Spain, Argentina and Italy. Hercules™ stents are available in Germany, Spain, Italy, Turkey, Argentina and Brazil, following CE approval in March 2021. At the end of the event, the experts expressed their appreciation for the event and their high recognition of the Endovastec™ brand. They also expressed their expectation that Endovastec™ could provide better solutions for vascular diseases in various countries and regions around the world. Zhenghua Miao, President of Endovastec™, said, “In the future, Endovastec™ will continue to organize more events under the international MasterClass series and build a bigger platform for experts from home and abroad to communicate and exchange knowledge, and to provide  trustworthy and universal access to state of art total solutions for patients worldwide. ”